Miruvor
Sign up
The short answer

What studies of Molnupiravir (Lagevrio) found

10papers on Molnupiravir (Lagevrio)
20,893patients in 2 health-record studies, counted apart from trials
0randomised trials, the strongest kind of study

At a glance, by condition

Preventing long COVID: B May help

Based on the strongest evidence, compared with another group, not randomised (low certainty), for overall symptoms.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Molnupiravir (Lagevrio) may help for preventing long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 10 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Molnupiravir (Lagevrio) · Preventing long COVID is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Preventing long COVID

Symptoms

Breathlessness2 studies · 20,893 people took Molnupiravir (Lagevrio) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; controlled studies found mixed results.

Compared with another group, not randomised2 studies · 238,707 people with results

Studies disagree about breathlessness.

Studies disagree about whether molnupiravir (Lagevrio) helps breathlessness. Mixed results · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 2 studies
  1. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. (2023)

    People in the study
    229,286 in the study
    Dose
    within five days after testing positive
    Outcome
    shortness of breath
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Inverse probability weighting; personal and health factors, clinical factors, healthcare utilization, pandemic-related characteristics, and drug-drug interaction categories. Personal and health factors for age, race (white, black, and other), sex (men or women), area of deprivation index, state of residency, BMI
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 8.0% eGFR, 9.1% BMI, and 3.9% blood pressure measurements missing; imputed using predictive mean matching Within the study cohort, 8.0% of the eGFR, 9.1% of the BMI, and 3.9% of the blood pressure measurements were missing.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  2. Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders. (2024)

    People in the study
    1,031,524 in the study · 9,421 with outcome data
    Dose
    —
    Outcome
    abnormal breathing
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (PSM) The demographic characteristics (i.e., age, sex, race, and socioeconomic status), comorbidities (hypertensive diseases, neoplasms, chronic lower respiratory diseases, overweight/obesity, type 2 diabetes mellitus, chronic kidney diseases, chronic liver disease, cardiovascular diseases and nicotine dependence)
    Selection of participants
    Moderate. comparison group: propensity score matching (PSM) The propensity score matching (PSM) method was used to match patients receiving molnupiravir (treated group) with those who did not (untreated group).
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Cognition (brain fog)2 studies · 20,893 people took Molnupiravir (Lagevrio) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance.

Compared with another group, not randomised2 studies · 238,707 people with results

Cognition (brain fog) improved more than in the comparison group.

The evidence is very uncertain about the effect of molnupiravir (Lagevrio) on cognition (brain fog) later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
See the 2 studies
  1. Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders. (2024)

    People in the study
    1,031,524 in the study · 9,421 with outcome data
    Dose
    —
    Outcome
    cognitive symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (PSM) The demographic characteristics (i.e., age, sex, race, and socioeconomic status), comorbidities (hypertensive diseases, neoplasms, chronic lower respiratory diseases, overweight/obesity, type 2 diabetes mellitus, chronic kidney diseases, chronic liver disease, cardiovascular diseases and nicotine dependence)
    Selection of participants
    Moderate. comparison group: propensity score matching (PSM) The propensity score matching (PSM) method was used to match patients receiving molnupiravir (treated group) with those who did not (untreated group).
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. (2023)

    People in the study
    229,286 in the study
    Dose
    within five days after testing positive
    Outcome
    neurocognitive impairment
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Inverse probability weighting; personal and health factors, clinical factors, healthcare utilization, pandemic-related characteristics, and drug-drug interaction categories. Personal and health factors for age, race (white, black, and other), sex (men or women), area of deprivation index, state of residency, BMI
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 8.0% eGFR, 9.1% BMI, and 3.9% blood pressure measurements missing; imputed using predictive mean matching Within the study cohort, 8.0% of the eGFR, 9.1% of the BMI, and 3.9% of the blood pressure measurements were missing.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Pain2 studies · 20,893 people took Molnupiravir (Lagevrio) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance.

Compared with another group, not randomised2 studies · 238,707 people with results

Pain improved more than in the comparison group.

The evidence is very uncertain about the effect of molnupiravir (Lagevrio) on pain later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
See the 2 studies
  1. Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders. (2024)

    People in the study
    1,031,524 in the study · 9,421 with outcome data
    Dose
    —
    Outcome
    chest/throat pain
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (PSM) The demographic characteristics (i.e., age, sex, race, and socioeconomic status), comorbidities (hypertensive diseases, neoplasms, chronic lower respiratory diseases, overweight/obesity, type 2 diabetes mellitus, chronic kidney diseases, chronic liver disease, cardiovascular diseases and nicotine dependence)
    Selection of participants
    Moderate. comparison group: propensity score matching (PSM) The propensity score matching (PSM) method was used to match patients receiving molnupiravir (treated group) with those who did not (untreated group).
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. (2023)

    People in the study
    229,286 in the study
    Dose
    within five days after testing positive
    Outcome
    muscle pain
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Inverse probability weighting; personal and health factors, clinical factors, healthcare utilization, pandemic-related characteristics, and drug-drug interaction categories. Personal and health factors for age, race (white, black, and other), sex (men or women), area of deprivation index, state of residency, BMI
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 8.0% eGFR, 9.1% BMI, and 3.9% blood pressure measurements missing; imputed using predictive mean matching Within the study cohort, 8.0% of the eGFR, 9.1% of the BMI, and 3.9% of the blood pressure measurements were missing.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Fatigue1 study · 9,421 people took Molnupiravir (Lagevrio) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised1,031,524 in the study · 9,421 with outcome data · the composite of all-cause hospitalization or death within 30 days and the risk of post-COVID-19 conditions up to a year after COVID-19 diagnosis

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of molnupiravir (Lagevrio) on fatigue later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders. (2024)

    People in the study
    1,031,524 in the study · 9,421 with outcome data
    Dose
    —
    Outcome
    fatigue
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (PSM) The demographic characteristics (i.e., age, sex, race, and socioeconomic status), comorbidities (hypertensive diseases, neoplasms, chronic lower respiratory diseases, overweight/obesity, type 2 diabetes mellitus, chronic kidney diseases, chronic liver disease, cardiovascular diseases and nicotine dependence)
    Selection of participants
    Moderate. comparison group: propensity score matching (PSM) The propensity score matching (PSM) method was used to match patients receiving molnupiravir (treated group) with those who did not (untreated group).
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Autonomic symptoms1 study · 11,472 people took Molnupiravir (Lagevrio) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised229,286 in the study · from 30 days after the first SARS-CoV-2 positive test result until end of follow-up · within five days after testing positive

No clear difference in autonomic symptoms.

The evidence is very uncertain about the effect of molnupiravir (Lagevrio) on autonomic symptoms later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. (2023)

    People in the study
    229,286 in the study
    Dose
    within five days after testing positive
    Outcome
    dysautonomia
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Inverse probability weighting; personal and health factors, clinical factors, healthcare utilization, pandemic-related characteristics, and drug-drug interaction categories. Personal and health factors for age, race (white, black, and other), sex (men or women), area of deprivation index, state of residency, BMI
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 8.0% eGFR, 9.1% BMI, and 3.9% blood pressure measurements missing; imputed using predictive mean matching Within the study cohort, 8.0% of the eGFR, 9.1% of the BMI, and 3.9% of the blood pressure measurements were missing.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome

Daily life and health overall

Overall symptoms1 study · 9,421 people took Molnupiravir (Lagevrio) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information).

Compared with another group, not randomised1,031,524 in the study · 9,421 with outcome data · the composite of all-cause hospitalization or death within 30 days and the risk of post-COVID-19 conditions up to a year after COVID-19 diagnosis

Overall symptoms improved more than in the comparison group.

Molnupiravir (Lagevrio) may improve overall symptoms later, when given during acute COVID. Improvement · low certainty B

  • Risk of bias couldn't be judged for most results (ROBINS-I: no information)
See the 1 study
  1. Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders. (2024)

    People in the study
    1,031,524 in the study · 9,421 with outcome data
    Dose
    —
    Outcome
    hospitalization or mortality
    Effect
    better
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. comparison group: propensity score matching (PSM) The demographic characteristics (i.e., age, sex, race, and socioeconomic status), comorbidities (hypertensive diseases, neoplasms, chronic lower respiratory diseases, overweight/obesity, type 2 diabetes mellitus, chronic kidney diseases, chronic liver disease, cardiovascular diseases and nicotine dependence)
    Selection of participants
    Moderate. comparison group: propensity score matching (PSM) The propensity score matching (PSM) method was used to match patients receiving molnupiravir (treated group) with those who did not (untreated group).
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Low. an objective measure
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Side effects

No study of this treatment alone reported side effects we could read.

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

All papers

  1. Early-Phase Oral Antiviral Use and Post-COVID-19 Condition in Outpatients.2026 · compared with another group · 8,657 in the study · 7,699 with outcome data
    Summary

    This prospective, nationwide, multicenter, registry-based cohort study enrolled outpatients with laboratory-confirmed COVID-19 at 51 acute-care hospitals in Japan. Of 8657 participants in the full analysis population, 7699 were included in the primary analysis population: 2181 received early oral antivirals (1698 ensitrelvir, 98 nirmatrelvir, 385 molnupiravir) and 5518 received no antiviral. Treatment duration was not reported. Follow-up assessments were at day 28 and day 84. The primary outcome was post–COVID-19 condition (PCC), defined as persistence of 1 or more of 5 prespecified symptoms with the same symptoms reported on both day 28 and day 84. Adjusted PCC risk was 21.5% with antivirals and 25.1% without antivirals (adjusted risk ratio 0.86; 95% CI 0.78 to 0.93; P < .001). For individual agents, ensitrelvir had an adjusted risk ratio of 0.86 (95% CI 0.79 to 0.95) and molnupiravir 0.81 (95% CI 0.67 to 0.98); nirmatrelvir had an adjusted risk ratio of 0.88 (95% CI 0.63 to 1.24; P = .47), which the authors report did not reach statistical significance. Failure to return to usual health by day 84 occurred in 9.9% versus 12.9% (adjusted risk ratio 0.77; 95% CI 0.67 to 0.89). For ensitrelvir, this was 9.7% versus 12.9% (adjusted risk ratio 0.75; 95% CI 0.64 to 0.88). Harms and withdrawals due to harms were not reported. Missing outcome data excluded 934 participants. The authors state that the observational design precludes causal inference and residual confounding cannot be excluded.

  2. Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders.2024 · compared with another group · 1,031,524 in the study · 9,421 with outcome data
    Summary

    This retrospective cohort study used the TriNetX research network to identify adult patients with pre-existing psychiatric disorders and non-hospitalized COVID-19 from 1 January 2022 to 1 May 2023. After exclusions, 1,031,524 patients were included: 9,426 in the molnupiravir group and 1,022,098 in the non-molnupiravir group before propensity score matching; after matching, two groups of 9,421 patients each were analysed. Molnupiravir was compared with not receiving molnupiravir; treatment duration was not reported. Outcomes were the composite of all-cause hospitalization or death within 30 days and post-COVID-19 conditions up to a year after diagnosis. During the 30-day follow-up, the treated group had a reduced risk of hospitalization or mortality (HR, 0.760; 95% CI, 0.665–0.869), and the composite outcome was lower than in the untreated group (log-rank test, p < 0.001). For post-COVID-19 conditions during the 1-year follow-up, the reported HRs included chest/throat pain (HR, 0.615; 95% CI, 0.543–0.696), abnormal breathing (HR, 0.761; 95% CI, 0.687–0.884), abdominal symptoms (HR, 0.748; 95% CI, 0.674–0.831), fatigue (HR, 0.718; 95% CI, 0.638–0.808), headache (HR, 0.753; 95% CI, 0.665–0.852), cognitive symptoms (HR, 0.769; 95% CI, 0.630–0.940), myalgia (HR, 0.647; 95% CI, 0.530–0.789), cough (HR, 0.867; 95% CI, 0.770–0.978), and palpitation (HR, 0.641; 95% CI, 0.534–0.770). Harms were not reported. The authors state limitations including possible coding errors, residual confounding, and not assessing the effect for each specific psychiatric disorder.

  3. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.2023 · compared with another group · 229,286 in the study
    Summary

    This cohort study used Veterans Affairs records to examine whether molnupiravir during the first five days of SARS-CoV-2 infection was associated with reduced risk of post-acute sequelae of SARS-CoV-2 (PASC). It included 229 286 participants who tested positive between 5 January 2022 and 15 January 2023 and had at least one risk factor for severe covid-19. Of these, 11 472 received molnupiravir within five days after testing positive and 217 814 received no covid-19 antiviral or antibody treatment. Post-acute outcomes were ascertained from 30 days after the first positive test until end of follow-up; the cohort was followed until 15 February 2023. Compared with no treatment, molnupiravir was associated with reduced risk of PASC (relative risk 0.86, 95% confidence interval 0.83 to 0.89; absolute risk reduction at 180 days 2.97%, 2.31% to 3.60%), with event rates at 180 days of 18.58% and 21.55%. Molnupiravir was associated with reduced risk of post-acute death (hazard ratio 0.62, 0.52 to 0.74; absolute risk reduction 0.87%, 0.62% to 1.13%), post-acute hospital admission (hazard ratio 0.86, 0.80 to 0.93; absolute risk reduction 1.32%, 0.72% to 1.92%), and the composite outcome (hazard ratio 0.82, 0.77 to 0.88; absolute risk reduction 2.00%, 1.37% to 2.62%). It was associated with reduced risk of eight of 13 post-acute sequelae; no statistically significant associations were observed for ischemic heart disease, diabetes, dysautonomia, shortness of breath, and cough. The paper did not report side effects or withdrawals related to harms. The authors stated the cohort was predominately white men, which may limit generalizability.

  4. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes.2022 · compared with another group · 112,380 in the study
    Summary

    This retrospective cohort study emulated three target randomized controlled trials in Veterans Health Administration outpatients at risk for severe COVID-19 who had a first positive SARS-CoV-2 test during January and February 2022. A total of 112,380 Veterans were identified. The comparisons were nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir-ritonavir versus molnupiravir; treatment duration was not reported. Matching left 1,587 nirmatrelvir-ritonavir-treated participants in trial 1, 897 molnupiravir-treated participants in trial 2, and 769 molnupiravir-treated participants in trial 3, matched to 534 unique nirmatrelvir-ritonavir-treated participants. Follow-up covered 30-day outcomes and 31–180-day outcomes. At 30 days, nirmatrelvir-ritonavir had a lower hospitalization or death rate than no treatment (28.36 versus 53.40 events per 1000 persons; RD −25.05, 95% CI −35.47 to −14.62), with lower death (RD −11.71, 95% CI −16.07 to −7.35) and hospitalization (RD −13.97, 95% CI −23.85 to −4.09). Molnupiravir versus no treatment was similar overall (44.59 versus 57.88 per 1000; RD −13.29, 95% CI −29.44 to 2.87), but among persons aged 65 years and older the RD was −27.10 (95% CI −50.63 to −3.58). Molnupiravir versus nirmatrelvir-ritonavir showed an insignificant RD of −14.30 (95% CI −33.20 to 4.59). Long-term outcomes showed no significant difference for nirmatrelvir-ritonavir versus no treatment; molnupiravir had higher acute or long-term care admission (123.0 versus 82.5 per 1000; SHR 1.48, 95% CI 1.11 to 1.99). Renal conditions were lower with nirmatrelvir-ritonavir (44.2 versus 65.1 per 100 persons; SHR 0.68, 95% CI 0.48 to 0.95). Side-effect counts and withdrawals were not reported.

  5. Corona With Lyme: A Long COVID Case Study.2023 · case report · 1 in the study
    Summary

    This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.

  6. Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients.2023 · case report · 3 in the study · 57 with outcome data
    Summary

    Researchers conducted a cohort study of nirmatrelvir and molnupiravir for post–COVID–19 condition (PCC or long COVID) in older patients. The cohort came from Medicare enrollees aged 65 years or older diagnosed with COVID-19 between January and September 2022. Among 3,975,690 outpatients with COVID-19, 57% remained in the study after exclusion; 19.5% received nirmatrelvir and 2.6% received molnupiravir. The comparison group received neither. PCC was identified as any new occurrence of 11 symptoms between 4 to 12 weeks after infection. PCC incidence was 11.8% among patients receiving nirmatrelvir, 13.7% for molnupiravir, and 14.5% for neither. Absolute risk reduction was 2.7% for nirmatrelvir and 0.8% for molnupiravir. Hazard ratios compared with no treatment were 0.87 (95% CI, 0.86-0.88; P < .001) for nirmatrelvir and 0.92 (95% CI, 0.90-0.94; P < .001) for molnupiravir. Sensitivity analysis of only patients with the COVID-19 code showed hazard ratios of 0.93 (95% CI, 0.92-0.94; P < .001) for nirmatrelvir and 0.96 (95% CI, 0.93-0.99; P = .001) for molnupiravir. An interaction analysis found significantly smaller effect sizes in females than males (nirmatrelvir: 0.89 vs 0.84; molnupiravir: 0.95 vs 0.88). No side effects or harms were reported. The authors state limitations include not incorporating vaccination status, use of prescription of the drugs as evidence of COVID-19, and restriction to patients 65 years or older.

  7. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.2024 · systematic review
    Summary

    This systematic review and network meta-analysis asked whether early oral antiviral drugs, including nirmatrelvir-ritonavir (NMV-r) and molnupiravir, reduce post COVID-19 condition (PCC) in adults with COVID-19. The authors searched PubMed, Web of Science, Embase, Cochrane, MedRxiv, and Psycinfo from inception until November 1, 2023. Nine observational studies containing 866,066 patients were included; the review compared oral antiviral drugs with no antiviral drug treatment. Treatment duration was not reported. In the pairwise meta-analysis, patients who received oral antiviral drugs had reduced PCC risk (RR 0.77, 95% CI [0.68–0.88]). Subgroup RRs versus no antiviral drug treatment were 0.76 (95% CI 0.65–0.88) for NMV-r and 0.88 (95% CI 0.82–0.94) for molnupiravir. In the network meta-analysis, RRs versus control were 0.75 [0.63–0.91] for NMV-r and 0.98 [0.69–1.39] for molnupiravir; NMV-r versus molnupiravir was 0.77 [0.53–1.12]. NMV-r had the highest ranking (SUCRA = 95.5%), followed by molnupiravir (SUCRA = 31.6%). One named cohort (Xie 2023 b; 281,793 patients) reported that NMV-r within 5 days of SARS-CoV-2 infection reduced PCC risk by 26%. Side-effect counts were not reported; the authors stated adverse effects and drug-drug interactions may limit application. They concluded early oral antiviral drugs may potentially protect against PCC in non-hospitalized patients with COVID-19.

  8. Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review.2025 · review
    Summary

    This scoping review asked which therapeutic agents can be used for post-acute sequelae of COVID-19 (PASC). The authors searched PubMed, Embase, and the Cochrane library for English studies published between January 1, 2020, and July 22, 2024; 413 studies were identified and 39 were included. The review did not report a total number of participants. Included reports measured symptoms such as fatigue, pain, cognitive function, olfactory function, pulmonary function, PASC incidence, hospitalization, and death. For metformin, among 1126 patients observed for nine months, 93 (9.3%) reported PASC, with a hazard ratio of 0.59 (95% CI 0.39–0.89; p = 0.012). Low-dose naltrexone showed a hazard ratio of 5.04 for improvement versus physical therapy alone among 108 patients (p = 0.02), and 52–67% of patients in observational studies reported improvements. In a randomized study of 30 patients with PASC and lung fibrosis, nintedanib and pirfenidone improved pulmonary function, 6MWT distance, and oxygen saturation over 12 weeks; nintedanib was associated with diarrhea (80%) and nausea/vomiting (66.6%). The STOP-PASC trial of a 15-day NMV-r course failed to show significant benefit. Ivermectin had no effect on PASC incidence in COVID-OUT, and remdesivir randomized trials showed no clear long-term benefit. The authors state limitations include heterogeneity of PASC symptoms and limited robust evidence.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime